OCULAR IMPLANT MARKET ANALYSIS

Ocular Implant Market, by Implant Type (Intraocular Lenses (IOL) (Aspheric IOLs, Toric IOLs, Multifocal IOLs, Anterior chamber IOLs, and others), Corneal Implants, Glaucoma Implants, Orbital Implants, Ocular prosthesis, and others), by Application (Glaucoma Surgery, Oculoplasty, Drug Delivery, Age-Related Macular Degeneration (AMD), Aesthetic purpose, and others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Sep 2022
Code : CMI2699
Pages :157
Formats :
Excel and PDF
Industry : Medical Devices

Market News

Increasing number of product launches are expected to drive growth of the global ocular implants market. For instance, in July 2018, Alcon, an ophthalmology company had launched its intraocular lens (IOL) portfolio including, Clareon AutonoMe IOL and delivery system, designed to provide easy and intuitive control during cataract surgery, at the Alcon-hosted Synergeyes clinical symposium in Sydney. AutonoMe is the first and only automated, disposable, preloaded IOL delivery system preloaded with the Clareon IOL, and it is automated with CO2-powered delivery mechanism. Moreover, in June 2018, Molteno Ophthalmic, medical device company launched its Molteno3 S-Series glaucoma implants at the 24th Greek Glaucoma.

Global Ocular Implant Market: Key Developments

In June 2022, EyePoint Pharmaceuticals, Inc., pSivida, Pharmaceutical Company, received Chinese regulatory body approval for an implant to treat a form of eye inflammation, becoming the first company to get a nod in the country based entirely on real-world data. Ocumension Therapeutics paid an initial $1.75 million to access EyePoint’s technology in 2018. Ocumension Therapeutics filed for National Medical Products Administration (NMPA) approval of Yutiq in April 2021. According to the biotech, the filing was the first submission for National Medical Products Administration approval of a sustained-release micro-insert with a controlled release rate of up to 36 months and the first time The positive National Medical Products Administration decision triggered a further claim, namely that Yutiq is the first medicine approved in China based entirely on real-world data. The Chinese regulator had accepted a new drug application based on real-world study data.

Increasing prevalence of corneal diseases is expected to increase demand for ocular implants.